TY - JOUR
T1 - Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie
AU - Loree, Jonathan M.
AU - Kopetz, Scott
AU - Raghav, Kanwal P.S.
N1 - Publisher Copyright:
© Journal of Gastrointestinal Oncology. All rights reserved.
PY - 2017
Y1 - 2017
N2 - While the treatment of colorectal cancer continues to rely heavily on conventional cytotoxic therapy, an increasing number of targeted agents are under development. Many of these treatments require companion diagnostic tests in order to define an appropriate population that will derive benefit. In addition, a growing number of biomarkers provide prognostic information about a patient's malignancy. As we learn more about these biomarkers and their assays, selecting the appropriate companion diagnostic becomes increasingly important. In the case of many biomarkers, there are numerous assays which could provide the same information to a treating physician, however each assay has strengths and weaknesses. Institutions must balance cost, assay sensitivity, turn-around time, and labor resources when selecting which assay to offer. In this review we will discuss the current state of companion diagnostics available in metastatic colorectal cancer and explore emerging biomarkers and their assays. We will focus on KRAS, BRAF, HER2, and PIK3CA testing, as well as microsatellite stability assessment and multigene panels.
AB - While the treatment of colorectal cancer continues to rely heavily on conventional cytotoxic therapy, an increasing number of targeted agents are under development. Many of these treatments require companion diagnostic tests in order to define an appropriate population that will derive benefit. In addition, a growing number of biomarkers provide prognostic information about a patient's malignancy. As we learn more about these biomarkers and their assays, selecting the appropriate companion diagnostic becomes increasingly important. In the case of many biomarkers, there are numerous assays which could provide the same information to a treating physician, however each assay has strengths and weaknesses. Institutions must balance cost, assay sensitivity, turn-around time, and labor resources when selecting which assay to offer. In this review we will discuss the current state of companion diagnostics available in metastatic colorectal cancer and explore emerging biomarkers and their assays. We will focus on KRAS, BRAF, HER2, and PIK3CA testing, as well as microsatellite stability assessment and multigene panels.
KW - Biomarker
KW - Colorectal cancer
KW - Companion diagnostic
KW - Next generation sequencing (NGS)
UR - http://www.scopus.com/inward/record.url?scp=85014408838&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85014408838&partnerID=8YFLogxK
U2 - 10.21037/jgo.2017.01.01
DO - 10.21037/jgo.2017.01.01
M3 - Review article
C2 - 28280626
AN - SCOPUS:85014408838
SN - 2078-6891
VL - 8
SP - 199
EP - 212
JO - Journal of Gastrointestinal Oncology
JF - Journal of Gastrointestinal Oncology
IS - 1
ER -